SOME SEE A GEARHEAD.

We see the nearly

Performing every tune up

ELOCTATE Prophylaxis Offers Bleed Protection*
You Can Count On.

SOME SEE A GEARHEAD.

We see the nearly

Performing
every tune up

ELOCTATE Prophylaxis Offers Bleed Protection*
You Can Count On.

Eloctate has you covered

You count on your joints more than you think. Do the math. Check out these numbers and read up on what ELOCTATE can do for you.

[SELECT ONE]

 Adults (12 years and older)

Children (Under 12 years old)

Facts About Bleed Protection*

In clinical studies of adults and adolescents using an individualized prophylaxis regimen:

Median Of Zero Joint Bleeds
Median Of Zero Joint Bleeds
100% Target Joints Resolved*

*ELOCTATE has been proven to help patients prevent bleeding episodes using a prophylaxis regimen.

In the A-LONG study, 164 adults and adolescents ages 12-65 received ELOCTATE either every 3 to 5 days, once weekly, or on demand. The ASPIRE extension study includes 150 people who completed A-LONG.

Data from patients treating prophylactically with ELOCTATE for at least 12 months, who had target joints at enrollment in ASPIRE. 234 out of 235 target joints were resolved. A target joint is defined as a major joint with 3 or more bleeding episodes in a consecutive 6-month period. Target joint resolution is defined as 2 or fewer spontaneous bleeds in a 12-month period.

Get Relief. Get Control.

In a clinical study of adults and adolescents treating on demand:

8/10 felt pain relief and/or notice improvement in bleeding with 1 infusion of ELOCTATE (n=75 Bleeds)

87% Of Bleeds Were Controlled With 1 Infusion (n=70 Bleeds)

On-demand treatment and control of bleed episodes

man sitting on a road bike in front of a landscape

I'm happy with the bleed and joint bleed protection I'm getting from my ELOCTATE prophy. And that’s important to me.

- Kenny, an ELOCTATE Peer

Note: This is a personal account of an ELOCTATE Peer. Please talk to your healthcare provider about whether ELOCTATE may be right for you. Individual results may vary.

Dosing That Lets You Do You

In clinical trials, 98.8% of patients were able to dose less frequently with ELOCTATE than with their prior standard half-life treatment.

With a variety of vial strength options, ELOCTATE offers individualized dosing and the potential for fewer infusions using a prophylaxis regimen.

bar graph of number of infusions
In a clinical study, ELOCTATE was shown to last 50% longer in the body than ADVATE®.2

(n=28)

See How We Stack Up

In clinical studies, ELOCTATE was shown to last 50% longer in the body than ADVATE®.

ADVATE® [Antihemophilic Factor (Recombinant)] is a registered trademark of Baxalta Incorporated, a Takeda company.

Fc Fusion and You

Just as the blades of a windmill harness naturally occurring wind to produce energy, Fc Fusion utilizes naturally occurring Fc receptors in your body to keep Factor VIII temporarily recirculating in your bloodstream.2-6 ELOCTATE is Factor VIII fused with an Fc protein.

For the scientist in you, check out this video with a little more detail about how Fc Fusion works.

Watch Video
illustration of a windmill

Wait! There’s more to
learn about ELOCTATE.

×

INDICATION ELOCTATE® [Antihemophilic Factor (Recombinant), Fc Fusion Protein] is an injectable medicine that is used to help control and prevent bleeding in people with Hemophilia A (congenital Factor VIII deficiency). Your healthcare provider may give you ELOCTATE when you have surgery.

Important Safety Information and Indication 

IMPORTANT SAFETY INFORMATION

Do not use ELOCTATE if you have had an allergic reaction to it in the past.

Tell your healthcare provider if you have or have had any medical problems, take any medicines, including prescription and non-prescription medicines, supplements, or herbal medicines, have any allergies, are breastfeeding, are pregnant or planning to become pregnant, or have been told you have inhibitors (antibodies) to Factor VIII.

INDICATION

ELOCTATE® [Antihemophilic Factor (Recombinant), Fc Fusion Protein] is an injectable medicine that is used to help control and prevent bleeding in people with Hemophilia A (congenital Factor VIII deficiency). Your healthcare provider may give you ELOCTATE when you have surgery.

Important Safety Information and Indication 

IMPORTANT SAFETY INFORMATION

Do not use ELOCTATE if you have had an allergic reaction to it in the past.

Tell your healthcare provider if you have or have had any medical problems, take any medicines, including prescription and non-prescription medicines, supplements, or herbal medicines, have any allergies, are breastfeeding, are pregnant or planning to become pregnant, or have been told you have inhibitors (antibodies) to Factor VIII.

Allergic reactions may occur with ELOCTATE. Call your healthcare provider or get emergency treatment right away if you have any of the following symptoms: difficulty breathing, chest tightness, swelling of the face, rash, or hives.

Your body can also make antibodies called "inhibitors" against ELOCTATE, which may stop ELOCTATE from working properly.

Additional common side effects of ELOCTATE are headache, rash, joint pain, muscle pain and general discomfort.

If you have risk factors for developing abnormal blood clots in your body, such as an indwelling venous catheter, treatment with Factor VIII may increase this risk.

These are not all the possible side effects of ELOCTATE. Talk to your healthcare provider right away about any side effect that bothers you or that does not go away, or if bleeding is not controlled after using ELOCTATE.

INDICATION

ELOCTATE® [Antihemophilic Factor (Recombinant), Fc Fusion Protein] is an injectable medicine that is used to help control and prevent bleeding in people with Hemophilia A (congenital Factor VIII deficiency). Your healthcare provider may give you ELOCTATE when you have surgery.

Please see Full Prescribing Information

MANUFACTURED BY

Bioverativ Therapeutics Inc.
Waltham, MA 02451 USA
U.S. License #2078

Click here to learn more about Sanofi's commitment to fighting counterfeit drugs.